Niagen Bioscience Management
Management Kriterienprüfungen 2/4
Niagen Bioscience CEO ist Rob Fried , ernannt in Jun 2018, hat eine Amtszeit von 7.92 Jahren. Die jährliche Gesamtvergütung beträgt $8.38M , bestehend aus 7.7% Gehalt und 92.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 2.09% der Aktien des Unternehmens, im Wert von $6.12M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.3 Jahre bzw. 9 Jahre.
Wichtige Informationen
Rob Fried
Geschäftsführender
US$8.4m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 7.71% |
| Amtszeit als Geschäftsführer | 7.9yrs |
| Eigentum des Geschäftsführers | 2.1% |
| Durchschnittliche Amtszeit des Managements | 6.3yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 9yrs |
Jüngste Management Updates
Recent updates
Narrativ-Update • May 14
NAGE: Core Demand And Injectables Will Drive Future Upside Potential
Niagen Bioscience's analyst price target has shifted from $13.60 to $12.60, as analysts adjust their models to slightly lower revenue growth, profit margin, and fair value assumptions while still highlighting ongoing demand in the core business and potential upside from the injectable segment. Analyst Commentary Recent research updates show a consistent pattern of price target reductions, with the latest move taking the blended target to US$12.60.Narrativ-Update • Apr 22
NAGE: Core Demand And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14, citing updated models after Q4 results that point to steady demand in the core business and possible upside from the injectable segment. Analyst Commentary Recent commentary around Niagen Bioscience centers on how updated Q4 models affect the risk and reward trade off, with attention on both the established core business and the injectable opportunity.Narrativ-Update • Apr 07
NAGE: Core Strength And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14, citing updated models after Q4 results that reflect steady demand in the core business and possible upside from the injectable segment. Analyst Commentary Analysts see the updated price target as largely reflecting model clean up after Q4, rather than a shift in the overall view on the business.Narrativ-Update • Mar 23
NAGE: Core Demand And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14. This reflects updated models after Q4 results that pointed to steady demand in the core business and potential upside from the injectable segment.Narrativ-Update • Mar 06
NAGE: Core Demand And Injectables Outlook Will Support Future Upside
Analysts have trimmed their 12 month price target on Niagen Bioscience from $16.04 to $13.60, citing updated models that reflect steady demand in the core business, potential upside in injectables, adjustments to revenue growth and profit margin assumptions, and a lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to steady demand in the core business as a key support for current valuation, suggesting the updated models still see the existing portfolio as a meaningful earnings driver.Seeking Alpha • Nov 15
Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years
Summary Niagen Bioscience delivered record Q3 revenue, rising 33% year-over-year, driven by strong Tru Niagen demand and accelerating distribution partnerships. Gross margin expanded to 64.5%, while operating income and adjusted EBITDA grew sharply, reflecting improving scale and cost discipline. Cash from operations already exceeded last year’s total, supporting a new $10 million share repurchase program. The FDA’s reversal on NMN introduces meaningful uncertainty for future demand and competitive dynamics in the NAD+ category. Niagen Bioscience remains financially strong, but sustained momentum in a post-NMN market is unproven, warranting a hold rating. Read the full article on Seeking AlphaAnalyseartikel • Nov 11
We Think Niagen Bioscience's (NASDAQ:NAGE) Profit Is Only A Baseline For What They Can Achieve
Even though Niagen Bioscience, Inc. ( NASDAQ:NAGE ) posted strong earnings, investors appeared to be underwhelmed. We...Analyseartikel • Nov 07
Niagen Bioscience, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Niagen Bioscience, Inc. ( NASDAQ:NAGE ) just released its quarterly report and things are looking bullish. The company...Analyseartikel • Oct 03
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 25% Cheaper Price Remains In Tune With Revenues
To the annoyance of some shareholders, Niagen Bioscience, Inc. ( NASDAQ:NAGE ) shares are down a considerable 25% in...Neues Narrativ • Aug 25
Wellness Adoption And Academic Trials Will Define Future Opportunity
Key Takeaways Expanding clinical credibility and global partnerships are opening new high-margin markets, broadening channels, and supporting scalable revenue growth with improved margins. Strong e-commerce performance and diversified product pipeline in preventive health provide resilience, reduced risk, and durable long-term earnings visibility.Narrativ-Update • Aug 08
Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects
Upward revisions to Niagen Bioscience's price target reflect positive clinical trial results confirming both safety and significant efficacy of its NAD+ supplementation, increased market confidence, and ongoing product and sales momentum, resulting in a higher consensus analyst price target rising from $14.90 to $15.84. Analyst Commentary Positive clinical study results published in a peer-reviewed journal demonstrated that Niagen Bioscience’s NAD+ supplementation is safe for patients with Werner syndrome and achieved a ~140% increase in blood NAD+ levels, along with improvements in liver, kidney, and arterial health markers.Analyseartikel • Aug 08
Niagen Bioscience, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
NasdaqCM:NAGE 1 Year Share Price vs Fair Value Explore Niagen Bioscience's Fair Values from the Community and select...Analyseartikel • Aug 06
What You Can Learn From Niagen Bioscience, Inc.'s (NASDAQ:NAGE) P/S After Its 28% Share Price Crash
NasdaqCM:NAGE 1 Year Share Price vs Fair Value Explore Niagen Bioscience's Fair Values from the Community and select...Analyseartikel • Jun 17
Market Participants Recognise Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Revenues Pushing Shares 29% Higher
Niagen Bioscience, Inc. ( NASDAQ:NAGE ) shares have continued their recent momentum with a 29% gain in the last month...Analyseartikel • May 10
Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
A week ago, Niagen Bioscience, Inc. ( NASDAQ:NAGE ) came out with a strong set of first-quarter numbers that could...Analyseartikel • Apr 05
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 30% Cheaper Price Remains In Tune With Revenues
The Niagen Bioscience, Inc. ( NASDAQ:NAGE ) share price has softened a substantial 30% over the previous 30 days...Analyseartikel • Mar 29
A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE)
Key Insights Niagen Bioscience's estimated fair value is US$7.18 based on 2 Stage Free Cash Flow to Equity Niagen...
Neues Narrativ • Feb 09
NIAGEN IV Expansion And FDA Approvals Will Unlock Future Opportunities
Expansion in clinics and strategic partnerships support revenue growth through increased e-commerce and pharmaceutical-grade product sales.Analyseartikel • Nov 07
ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors
ChromaDex Corporation's ( NASDAQ:CDXC ) strong earnings report was rewarded with a positive stock price move. We did...Analyseartikel • Nov 05
Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%
Despite an already strong run, ChromaDex Corporation ( NASDAQ:CDXC ) shares have been powering on, with a gain of 70...Analyseartikel • Jul 25
ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company
Those holding ChromaDex Corporation ( NASDAQ:CDXC ) shares would be relieved that the share price has rebounded 25% in...Analyseartikel • Jun 15
Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable
Key Insights ChromaDex's Annual General Meeting to take place on 20th of June Total pay for CEO Rob Fried includes...Analyseartikel • Jun 05
Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump
ChromaDex Corporation ( NASDAQ:CDXC ) shares have retraced a considerable 26% in the last month, reversing a fair...Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$19m |
| Dec 31 2025 | US$8m | US$646k | US$17m |
| Sep 30 2025 | n/a | n/a | US$20m |
| Jun 30 2025 | n/a | n/a | US$18m |
| Mar 31 2025 | n/a | n/a | US$14m |
| Dec 31 2024 | US$1m | US$500k | US$9m |
| Sep 30 2024 | n/a | n/a | US$1m |
| Jun 30 2024 | n/a | n/a | -US$1m |
| Mar 31 2024 | n/a | n/a | -US$4m |
| Dec 31 2023 | US$1m | US$500k | -US$5m |
| Sep 30 2023 | n/a | n/a | -US$6m |
| Jun 30 2023 | n/a | n/a | -US$6m |
| Mar 31 2023 | n/a | n/a | -US$11m |
| Dec 31 2022 | US$1m | US$500k | -US$17m |
| Sep 30 2022 | n/a | n/a | -US$20m |
| Jun 30 2022 | n/a | n/a | -US$28m |
| Mar 31 2022 | n/a | n/a | -US$27m |
| Dec 31 2021 | US$1m | US$500k | -US$27m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$21m |
| Dec 31 2020 | US$1m | US$519k | -US$20m |
| Sep 30 2020 | n/a | n/a | -US$23m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$30m |
| Dec 31 2019 | US$2m | US$487k | -US$32m |
Vergütung im Vergleich zum Markt: RobDie Gesamtvergütung ($USD8.38M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD1.74M).
Entschädigung vs. Einkommen: RobDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.
Geschäftsführer
Rob Fried (65 yo)
7.9yrs
Amtszeit
US$8,381,900
Vergütung
Mr. Robert N. Fried, also known as Rob, has been the Chief Executive Officer of Niagen Bioscience, Inc. (formerly known as ChromaDex Corporation) since June 22, 2018 and its a Director since July 2015. Mr....
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Co-Founder & Chairman | 26.3yrs | US$268.08k | 2.91% $ 8.5m | |
| CEO & Director | 7.9yrs | US$8.38m | 2.09% $ 6.1m | |
| CFO & Principal Accounting Officer | 1.6yrs | US$648.24k | 0.012% $ 35.2k | |
| Senior VP & General Counsel | 1.8yrs | US$558.01k | 0.0028% $ 8.3k | |
| Senior Vice President of Global Regulatory & Scientific Affairs | 6.3yrs | keine Daten | keine Daten | |
| Chief Marketing Officer | 1.5yrs | keine Daten | keine Daten | |
| Managing Director of Asia Pacific | 7.6yrs | keine Daten | keine Daten | |
| Head of Media Relations & Partnerships | no data | keine Daten | keine Daten | |
| Controller | no data | US$374.47k | 0.28% $ 819.7k | |
| Vice President of Finance | no data | keine Daten | keine Daten | |
| Assistant Controller | no data | keine Daten | keine Daten |
6.3yrs
Durchschnittliche Betriebszugehörigkeit
49yo
Durchschnittliches Alter
Erfahrenes Management: Das Managementteam von NAGE ist erfahren und erfahren (durchschnittliche Amtszeit von 6.3 Jahren).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Co-Founder & Chairman | 26.3yrs | US$268.08k | 2.91% $ 8.5m | |
| CEO & Director | 10.8yrs | US$8.38m | 2.09% $ 6.1m | |
| Member of Scientific Advisory Board | 8.9yrs | keine Daten | keine Daten | |
| Lead Independent Director | 9.2yrs | US$293.08k | 0.0088% $ 25.7k | |
| Chairman of the Scientific Advisory Board | 11.8yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 11.7yrs | keine Daten | keine Daten | |
| Independent Director | 4.1yrs | US$265.58k | 0% $ 0 | |
| Non-Executive Director | 8.8yrs | US$243.08k | 0% $ 0 | |
| Independent Director | 4.1yrs | US$258.08k | 0% $ 0 | |
| Chief Scientific Advisor & Member of Scientific Advisory Board | 11.7yrs | keine Daten | keine Daten | |
| Member of the Scientific Advisory Board | 6.8yrs | keine Daten | keine Daten | |
| Non-Executive Director | 4.4yrs | US$245.58k | 0% $ 0 |
9.0yrs
Durchschnittliche Betriebszugehörigkeit
64yo
Durchschnittliches Alter
Erfahrener Vorstand: NAGEDie Vorstandsmitglieder gelten als erfahren (9 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/20 08:06 |
| Aktienkurs zum Tagesende | 2026/05/20 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Niagen Bioscience, Inc. wird von 8 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Susan Anderson | Canaccord Genuity |
| Jeffrey Mark | Farmhouse Equity Research |